White Papers
Challenges in Oligonucleotide Therapeutics
Improvement of Vivarium Biodecontamination through Data-acquisition Systems and Automation
Safety and tolerability of a liquid bovine rotavirus pentavalent vaccine (LBRV-PV) in adults
Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment
Point of View
Has the Age of Antisense Oligonucleotides Finally Arrived?
Mitigating Positive Food Effect
The World of Biologics at Syngene Evolution and Growth- Part 2
The World of Biologics at Syngene Evolution and Growth- Part 1
An Introduction To Design of Experiments Methodology for Process Optimization
How the Right CRO Partner for Integrated CMC can Help Expedite Early Phase Development of Small Molecules
Adapting to Advances in Injectable Drug Delivery
DILI Assessment and Prediction By Syngene’s Heptox™ Platform
A Systematic Approach towards Chiral Method Development for Early Phase Product Development
Safety At Syngene
Target Dossiers for Validation
Formulation Development Strategies to Enable Quick First In Human (FIH) Study
The Quest for Talent That Matters
Dedicated R&D Centres Evolve, Engage & Empower
Targeting RNA With Small Molecules - A Viable Approach?
By Dr. Rakesh Paul
Native Chemical Ligation: A Primer
By Dr. Rajesh Sankaranarayanan
Syngene’s Supply Chain Management Improves Efficiency
Targeted Protein Degradation – An Emerging Platform for Drug Discovery
By Subhendu Kumar
State of the art Antibody Discovery Approaches
By Jayashree Aiyar
The USFDA’s Bioanalytical Method
Validation Guidance for Industry 2018
Ends Don’t Justify the Means
How CDMOs can create customer value through QbD?
